• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Qilian International Holding Group Ltd.

    6/4/24 9:25:25 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QLI alert in real time by email
    6-K 1 tm2416321d1_6k.htm FORM 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of June 2024

     

    Commission File Number: 001-39805

     

    Qilian International Holding Group Ltd

     

    No. 152 Hongliang East 1st Street, No. 1703,

    Tianfu New District, Chengdu, 610200

    People’s Republic of China

    +86-028-64775180

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F x Form 40-F ¨

     

     

     

     

     

     

    Change of Directors

     

    On May 29, 2024, Ms. Song Gao notified Qilian International Holding Group Ltd (the “Company”) of her resignation as a director, the chairperson of the nominating and corporate governance committee, and a member of the compensation committee and the audit committee of the Company, effective immediately. Ms. Gao has advised that her resignation was due to personal reasons and not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company.

     

    On May 29, 2024, Mr. Dingqian Liu notified the Company of his resignation as a director of the Company, effective immediately. Mr. Liu has advised that his resignation was due to personal reasons and not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company.

      

    To fill in the vacancies created by the resignation of Ms. Gao, on May 31, 2024, the board of directors (the “Board”) of the Company appointed Ms. Waihua Xu to serve as an independent director of the Company, effective immediately. Ms. Xu will act as the chairperson of the nominating and corporate governance committee and a member of the compensation committee and the audit committee.

     

    The following is the biographical information of Ms. Xu.

     

    Ms. Waihua Xu, aged 31, has acquired a wealth of experience in marketing and public relations. Since Auguest 2023, Ms. Xu has been the head of social media and UGC community teams at Shenzhen Geruidi Technology, Ltd., responsible for content operations. From June 2021 to August 2023, Ms. Xu worked at Shenzhen Yiyu Technology, Ltd., as the head of overseas new media operations. From August 2016 to June 2021, Ms. Xu worked as the customer manager at HomilyChart Canada Inc, responsible for developing and implementing marketing plan. Ms. Xu obtained her master’s degree in Leadership from Trinity Western University in 2019 and her bachelor’s degree in English from Hunan Institute of Engineering in 2016.

     

    Ms. Xu will receive annual cash compensation of $8,400, payable in monthly installments of $700. Ms. Xu does not have a family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.

     

    A copy of the director offer letter of Ms. Xu is attached hereto as exhibit 10.1.

     

    To fill in the vacancy created by the resignation of Mr. Liu, on May 31, 2024, the Board appointed Ms. Furong Cao to serve as a director of the Board, effective immediately.

     

    The following is the biographical information of Ms. Cao.

     

    Ms. Furong Cao, aged 54, is an experienced professional in business management. She has acquired a wealth of business management experience across a diverse range of industries, such as medical technology, pharmaceuticals, finance, and management consulting. Since July 2021, Ms. Cao has served as the director of operations of Shenzhen Financial Investment Service Co., Ltd., responsible for overseeing the investment strategies. From July 2017 to June 2021, Ms. Cao served as the business director of Shenzhen Beida Sequoia Business Management Co., Ltd., where she was responsible for financial project planning and investment risk assessment. Ms. Cao obtained her bachelor’s degree in Medical Profession from Shanghai Second Medical College in 1993.

     

    Ms. Cao will receive annual cash compensation of $8,400, payable in monthly installments of $700. Ms. Cao does not have a family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.

     

    A copy of the dicretor offer letter of Ms. Cao is attached hereto as exhibit 10.2.

     

     

     

     

    Change of CEO and CFO

     

    On May 31, 2024, Mr. Zhanchang Xin notified the Company of his resignation as the chief executive officer of the Company (the “CEO”), effective immediately. He has advised that his resignation was due to personal reasons and not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company. Mr. Zhanchang Xin will remain as the chairman of the Board of the Company.

     

    On May 31, 2024, Ms. Haiping Shi notified the Company of her resignation as the chief financial officer of the Company (the “CFO”), effective immediately. She has advised that her resignation was due to personal reasons and not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company.

      

    To fill in the vacancy created by the resignation of Mr. Zhanchang Xin, on May 31, 2024, the Board appointed Mr. Chen Xin to serve the CEO of the Company, effective immediately.

     

    The following is the biographical information of Mr. Chen Xin.

     

    Mr. Chen Xin, aged 31, was workding as an algorithm engineer at Geely Auti Holdings Limited from August 2022 to February 2024, where he led a team in developing perception algorithms for autonomous driving systems. From June 2021 to August 2022, he was an algorithm engineer at Shenzhen DJ Innovatives, where he engineered on image processing algorithms for autonomous driving vehicles. Mr. Xin obtained his bachelor’s degree in Physics from Sichuan University in 2016 and his master’s degree in Physics from National University of Singapore in 2019.

     

    Mr. Chen Xin will receive a monthly compensation of $2,000 in cash. Mr. Chen Xin is the son of Mr. Zhanchang Xin, and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.

     

    A copy of the employment agreement of Mr. Chen Xin is attached hereto as exhibit 10.3.

     

    To fill in the vacancy created by the resignation of Ms. Haiping Shi, on May 31, 2024, the Board appointed Ms. Yaxuan Zhai to serve the CFO of the Comapny, effective immediately.

     

    The following is the biographical information of Mr. Chen Xin.

     

    Ms. Yaxuan Zhai, aged 29, has been the finance manager at the Company since October 2023. She worked as an auditor at Baker Tilly China Certified Public Accountants from November 2022 to October 2023.   Ms. Zhai obtained her bachelor’s degree in Investment from Fujian Jiangxia University in 2018 and her master’s degree in Finance from The University of Sheffield in 2021.

     

    Ms. Yaxuan Zhai will receive a monthly compensation of $2,000 in cash. Ms. Yaxuan Zhai does not have a family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.

     

    A copy of the employment agreement of Ms. Yaxuan Zhai is attached hereto as exhibit 10.4.

     

     

    SUBMITTED HEREWITH

     

    Exhibits:

     

      10.1 Offer Letter to Ms. Xu
      10.2 Offer Letter to Ms. Cao
      10.3 Employment Agreement with Mr. Chen Xin
     

    10.4

     

    Employment Agreement with Ms. Yaxuan Zhai

     

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Dated: June 4, 2024

     

      Qilian International Holding Group Ltd.
         
      By: /s/ Chen Xin
      Name:  Chen Xin
      Title: Chief Executive Officer

     

     

    Get the next $QLI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QLI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QLI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Qilian International Holding Group Ltd. Announces Trading Ticker Symbol to "BGM"

    CHENGDU, China, Aug. 13, 2024 /PRNewswire/ -- Qilian International Holding Group Ltd. ("Qilian" or the "Company") (NASDAQ:QLI), a China-based pharmaceutical and chemical products manufacturer, announced today that effective on August 11, 2024, its Class A ordinary shares will begin trading on the Nasdaq Capital Market under the ticker symbol "BGM". The new ticker symbol will replace the Company's current ticker symbol "QLI." No action by the Company's shareholders is required with respect to the ticker symbol change. The Company's Class A ordinary shares will continue to be listed on the Nasdaq Capital Market and the CUSIP number remains unchanged. About Qilian International Holding Group L

    8/13/24 8:00:00 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qilian International Holding Group Ltd Regained Compliance with Nasdaq's Minimum Bid Price Rule

    CHENGDU, China, July 12, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ:QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced that on July 10, 2024, NASDAQ notified the Company that it has determined that for the 10 consecutive business days, from June 21, 2024 to July 9, 2024, the closing bid price of the Company's Class A ordinary shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and NASDAQ has closed this matter. About Qilian International Holding Group Ltd Qilian International Holding Group Ltd, headquartered in Gansu, China, is

    7/12/24 8:30:00 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qilian International Holding Group Limited Announces 1 for 5 Reverse Share Split

    CHENGDU, China, June 18, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ:QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, announced today that an 1 for 5 reverse split of its authorized share capital, was approved by the Company's board of directors on May 29, 2023 and will become effective on June 21, 2024. In connection with the reverse share split, the Company's shareholders will receive one new Class A ordinary share or Class B ordinary share of the Company for every five Class A ordinary shares or every five Class B ordinary shares they hold, respectively. The Company's Class A ordinary shares are expected to begi

    6/18/24 8:30:00 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QLI
    SEC Filings

    View All

    SEC Form 6-K filed by Qilian International Holding Group Ltd.

    6-K - Qilian International Holding Group Ltd (0001779578) (Filer)

    6/6/24 4:15:24 PM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Qilian International Holding Group Ltd.

    6-K - Qilian International Holding Group Ltd (0001779578) (Filer)

    6/4/24 9:25:25 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Qilian International Holding Group Ltd.

    EFFECT - Qilian International Holding Group Ltd (0001779578) (Filer)

    5/17/24 12:15:27 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QLI
    Financials

    Live finance-specific insights

    View All

    Qilian International Holding Group Ltd Declares Special Cash Dividends to Shareholders

    JIUQUAN, China, Feb. 16, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd ((the ", Company", NASDAQ:QLI), a China-based pharmaceutical and chemical products manufacturer, announced today that the Company has declared a special one-time cash dividend of $0.05 per ordinary share, payable in cash on or about March 6, 2023, to shareholders of record on February 28, 2023. "Despite the impacts of COVID-19 on us in our last fiscal year, the Company maintained decent operating results and healthy cash flow. We expect better financial results as China announced a rollback of its anti-COVID measures." said Mr. Zhanchang Xin, CEO of the Company. About Qilian International Holding Group Ltd Q

    2/16/23 4:30:00 PM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care